Beckman Coulter Life Sciences’ Post

Nectin-4: an attractive therapeutic target in multiple solid tumors 😃 #News According to the latest data of Padcev disclosed by Seagen at the 2024 ASCO, EV+P nearly doubled median progression-free survival and overall survival vs PBC in patients (pts) with previously untreated la/mUC in the phase 3 EV-302 trial.🎉 Enfortumab vedotin is an antibody-drug conjugate comprised of a human monoclonal antibody directed to Nectin-4 and monomethyl auristatin E, a microtubule-disrupting agent. Findings validate nectin-4 as an attractive therapeutic target in multiple solid tumors and support further clinical development, investigation, and application of nectin-4-targeting ADCs. 👉Check out our Nectin-4 catalog: https://lnkd.in/g3nXAhUZ 📧 [email protected] #celllinedevelopment #cancertreatment #drugdiscovery #Nectin-4 #CancerResearch #Immunotherapy #CancerTherapy #ADC

We are thrilled to announce the launch of our Global Clinical Oncology Biomarker Testing Market Report, which states that the global clinical oncology biomarker testing market is predicted to reach $12.6B by 2028. The second edition of this report takes a comprehensive look at clinical predictive and prognostic biomarker testing in oncology, summarizing both present and future (2023-2028) use. It provides quantitative and qualitative assessment of key market segments (e.g., cancer type, analyte, technology class, business model, sample type, and geography). In addition, this report details marker drivers (e.g., growing number of predictive markers), moderators (e.g., lack of access to precision medicine therapeutics in certain markets), trends, and profiles of top players in the space. Learn more about DeciBio’s Clinical Oncology Biomarker Testing Market Report – Second Edition: 2023-2028 on our website: https://lnkd.in/ePiv3qYT Check out the full press release here: https://lnkd.in/e9TrtZJ6. #precisiononcology #biomarkertesting #companiondiagnostics #NGS #PCR #IHC

🚀𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝘃𝗲 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀 𝗶𝗻 𝗰𝗼𝗺𝗯𝗮𝘁𝗶𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗶𝗻𝗳𝗹𝗮𝗺𝗺𝗮𝘁𝗼𝗿𝘆 𝗱𝗶𝘀𝗲𝗮𝘀𝗲𝘀🌟 Explore our new molecules in stock: the nanoparticle Paclitaxel (Abraxane®) and the mAb Lebrikizum (Ebglyss®)! Paclitaxel, a potent chemotherapy medication, disrupts the growth of cancer cells by stabilizing microtubules, crucial structures for cell division. On the other hand, lebrikizumab is a monoclonal antibody designed to target interleukin-13 (IL-13), a protein involved in allergic and inflammatory responses. Both licensed molecules represent innovative approaches in combating cancer and inflammatory diseases, offering hope for improved patient outcomes. 🌟 Get the therapeutic Paclitaxel and Lebrikizumab as lab consumables from the original drugs in our online shop (Link in the comments). Discover global access, reliable sourcing, and research benefits! 🌐💼 #InnovationInMedicine #ResearchAndDevelopment #ClinicalGradeMolecules #Evidentic #Antibody #mAb #ClinicalGrade #DrugDevelopment #DrugDiscovery

We released our Friends of Cancer Research 2023 Scientific Report today: bit.ly/3SE0bml. The report contains all of our white papers and publications to serve as a resource for those in the drug development and regulatory space. Over the course of 2023 our work touched on several key themes: 1. Patient-Focused Drug Development: Advancing Patient-Centered Technologies and Trial Designs 2. Real-World Evidence: Leveraging RWD for Insights on Real-World Response 3. Innovative Drug Development: Insights for Advancing Oncology Trials and Therapies 4. Complex Biomarkers: Aligning Best Practices to Support Future Utilization Through our collaborations and expertise from our partners, we are able to develop proposals and solutions that help shape and inform the landscape of oncology drug development and regulatory policy to bring advancements in treatment to patients. Read the full report here: bit.ly/3SE0bml #FriendsSR23 #cancerresearch #regulatoryscience #breakthroughs

A new report from PatientView delivers a powerful message to the pharma industry: patient-centricity is non-negotiable. This annual survey collects feedback from over 2,500 patient groups globally, highlighting that only 26% of these groups believe pharma is “Excellent” or “Good” at involving patient groups in R&D—a critical area for diseases like ALK+ lung cancer, where innovative treatments are urgently needed. The report emphasises the urgent need for pharmaceutical companies to intensify their focus on targeted treatments for unique subsets of patients. As patient groups seek greater involvement in research and development, a path we staunchly advocate for, it is clear the industry must adapt more inclusively. As pharma seeks to rebuild trust post-Covid, we must ensure that voices like ours are not just heard but are instrumental in shaping the therapies of tomorrow. #ALKPositive #LungCancerAwareness #PatientCentricity #PharmaNews

Unlocking #precisiononcology with FGFR Inhibition in #urothelialcarcinoma #bladdercancer - how do we further develop FGFR inhibitors in this disease? Might all of the following play a role: 1) understanding resistance, 2) optimal combinations (?PD1 inh, EV, PI3K/AKT inh), 3) optimal trial paradigms (?tumor agnostic basket trials), 4) earlier disease settings, 5) optimize delivery for better therapeutic index (intravesical)- honored to write this editorial in Annals of Oncology Annals of Oncology with esteemed coauthor Vivek Subbiah, MD Sarah Cannon Research Institute regarding paper by Andrea Necchi on pemigatinib for this disease

If you focus on oncology research and need data analysis for: 🔵 Drug target identification and validation 🔵 Biomarker identification for mechanism of action or drug efficacy 🔵 Biomarker prediction for patient stratification We can help! ⬇️Check the link in our comment below to discover our oncology services!⬇️

Immutep Limited is pleased to provide an update on its activities for the quarter ended 30 June 2024 (Q4 FY24). Highlights include:   - Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate efti in combination with KEYTRUDA® and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trial - Continuing positive clinical data reported from efti - Positive regulatory feedback received from Spanish Agency for Medicines and Health Products Competent Authority regarding the upcoming TACTI-004 Phase III trial - Appointed Centre for Human Drug Research to conduct Phase I trial to evaluate IMP761, a first-in-class LAG-3 agonist antibody designed to treat autoimmune diseases - Exclusive license agreement signed with Cardiff University / Prifysgol Caerdydd for development of an orally available, small molecule anti-LAG-3 therapy to treat cancer - A$100.2 million equity underwritten financing completed - Immutep cash runway extended to the end of calendar year 2026, with a strong cash totalling approximately A$181.8 million   Read the full ASX announcement here: https://bit.ly/4c6BJQZ   #LAG3 #immunotherapy #biotechnology #oncology

Join us for our upcoming webinar where our speakers will delve into the latest data from ASCO and recent conferences, highlighting opportunities to escalate treatment for high-risk populations across tumor types and treatment settings. Highlights you can expect: - In the MonarchE study, ctDNA+ in the adjuvant setting was highly prognostic of clinical outcomes in breast cancer. - A multi-institutional analysis revealed that ctDNA-positivity impacted the care plan of 91% of patients analyzed. - In gastroesophageal cancer, ctDNA results in the peri-operative setting correlated with long-term outcomes. - Patients with bladder cancer who remained MRD-negative on serial testing showed exceptional outcomes. - MRD-positive Signatera patients in head & neck cancer had inferior PFS post-treatment. - Results from the MD Anderson INTERCEPT program showed promising outcomes in colorectal cancer treatment. Signatera has been tested across >150,000 real-world patients and >500,000 longitudinal timepoints to-date. You can reach out to me or the Natera team (link in bio to schedule time) to learn about Natera's RWD, particularly the power of a molecular measure of response to therapy or likelihood to relapse. https://lnkd.in/g8GuDSnr

Industry Update: - AstraZeneca-Daiichi's Dato-DXd didn't prove OS benefit in phase 3. - J&J scoops up another atopic dermatitis drug for $1.25B. - FDA clears Galvanize's pulsed field ablation needle in cancer. - Gilead draws up $20M pact with cancer biotech Cartography. - Insmed's shares double as lung disease med powers past phase 3. - Arrowhead's cholesterol drug hits the mark again in phase 2 trial. #IndustryUpdate #Biotech #Pharmaceuticals